114 related articles for article (PubMed ID: 1854589)
1. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Fujioka K; Takada Y; Uchida S; Onoda T; Orita K
Biotherapy; 1991; 3(3):203-9. PubMed ID: 1854589
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
Fujiwara T; Sakagami K; Orita K
J Cancer Res Clin Oncol; 1990; 116(2):141-8. PubMed ID: 2324156
[TBL] [Abstract][Full Text] [Related]
3. Enhanced activity against syngeneic murine tumors by intrasplenic injection of recombinant interleukin-2 (IL-2) and interleukin-1 (IL-1).
Nakajima I; Ozaki M; Jinnai H; Shilayama Y; Hirohata T; Okuno K; Yasutomi M
Cancer Biother; 1993; 8(4):319-26. PubMed ID: 7804373
[TBL] [Abstract][Full Text] [Related]
4. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Wang C; Chai L; Zhu G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
[TBL] [Abstract][Full Text] [Related]
5. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 and syngeneic bone marrow transplantation in a murine fibrosarcoma model.
Ho SP; Stebler B; Ershler WB
Lymphokine Cytokine Res; 1991 Apr; 10(1-2):101-4. PubMed ID: 1873353
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of anti-tumor effect of interleukin 2 with sizofiran in mice.
Ikeuchi K
Keio J Med; 1991 Sep; 40(3):132-8. PubMed ID: 1753556
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.
Belardelli F; Ciolli V; Testa U; Montesoro E; Bulgarini D; Proietti E; Borghi P; Sestili P; Locardi C; Peschle C
Int J Cancer; 1989 Dec; 44(6):1108-16. PubMed ID: 2606579
[TBL] [Abstract][Full Text] [Related]
10. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
11. Use of N-acetyl cysteine to increase intracellular glutathione during the induction of antitumor responses by IL-2.
Yim CY; Hibbs JB; McGregor JR; Galinsky RE; Samlowski WE
J Immunol; 1994 Jun; 152(12):5796-805. PubMed ID: 8207209
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of interleukin-1 beta in the double grafted tumor system.
Ebina T; Ishikawa K
Jpn J Cancer Res; 1989 Jun; 80(6):570-6. PubMed ID: 2503477
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy by a slow delivery system of interleukin-2 in mice models.
Matsuoka J; Sakagami K; Fujiwara T; Onoda T; Idani H; Gochi A; Orita K
Acta Med Okayama; 1993 Apr; 47(2):79-84. PubMed ID: 8506753
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with low-dose interleukin-2 and a polysaccharopeptide derived from Coriolus versicolor.
Mao XW; Archambeau JO; Gridley DS
Cancer Biother Radiopharm; 1996 Dec; 11(6):393-403. PubMed ID: 10851500
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
16. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
[TBL] [Abstract][Full Text] [Related]
17. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with low-dose interleukin-2 and anti-transforming growth factor-beta antibody in a murine tumor model.
Mao XW; Kettering JD; Gridley DS
Cancer Biother; 1994; 9(4):317-27. PubMed ID: 7719379
[TBL] [Abstract][Full Text] [Related]
19. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
20. Augmentation of murine lymphokine-activated killer cell cytotoxicity by beta-cyclodextrin-benzaldehyde.
Kuroki Y; Ochiai H; Kurokawa M; Niwayama S; Kishimoto C; Tazawa K; Fujimaki M
J Cancer Res Clin Oncol; 1991; 117(2):109-14. PubMed ID: 2007609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
